2026 Chemotherapy FDA 
PharmaVoice
JULY 8, 2025
This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer. The FDA approved the first MEK inhibitor, a melanoma drug from Novartis, in 2013.
Pharmacy Times
JUNE 27, 2025
SHOW MORE The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma. Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 1, 2025
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.
pharmaphorum
JUNE 8, 2022
Patients also have to undergo lymphodepleting chemotherapy to help prepare the body for the CAR-T cells. With Lunsumio, patients do not have to wait to start treatment and avoid the need for chemotherapy, which can sometimes not be an option at all for people who are frail.
pharmaphorum
FEBRUARY 14, 2022
Padcev (enfortumab vedotin) is already approved as a second-line therapy for urothelial carcinoma (UC) after cisplatin chemotherapy and immunotherapy with checkpoint inhibitors, but Seagen and Astellas are working towards earlier use of the drug. billion-a-year product in 2026, according to GlobalData.
pharmaphorum
OCTOBER 11, 2020
The phase 3 PENELOPE-B trial was testing the CDK4/6 inhibitor as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant (pre-surgery) chemotherapy, but failed to show an improvement on the main measure of improved disease-free survival (iDFS).
Roots Analysis
OCTOBER 4, 2023
During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy.
Expert insights. Personalized for you.
Let's personalize your content